Drug
Anlotinib Hydrochloride plus Docetaxel
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Other(4)
Detailed Status
unknown4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
unknown4100%
Recent Activity
0 active trials
Showing 4 of 4
unknownphase_2
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
NCT04619537
unknownphase_2
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
NCT04619563
unknownphase_2
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
NCT03750916
unknownphase_2
Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
NCT03735264
Clinical Trials (4)
Showing 4 of 4 trials
NCT04619537Phase 2
A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
NCT04619563Phase 2
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
NCT03750916Phase 2
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
NCT03735264Phase 2
Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4